用大分子化疗剂解决癌症耐药性问题
Nathaniel H Park1, Wei Cheng2, Fritz Lai3
1IBM Research-Almaden , 650 Harry Road , San Jose , California 95120 United States.
通过破坏癌细胞膜, 克服抗药性. 这些自组装纳米颗粒对抗抗性和干癌细胞具有强烈的活性,防止迁移和抗性发展.
科学领域:
- 生物化学
- 材料科学
- 癌症学
背景情况:
- 抗药性是癌症化疗的主要挑战.
- 像多克索鲁比辛这样的现有治疗方法可以诱导耐药性,并且对耐药性和干细胞的有效性较低.
研究的目的:
- 设计和评估一种新型的自我组装的大分子化疗药物.
- 评估它们对抗耐药癌细胞,癌症干细胞和体内模型的有效性.
主要方法:
- 合成的性聚合物可以自组合成纳米粒子.
- 在体外对多种癌细胞系进行测试,包括耐药和癌细胞干细胞.
- 在肝细胞癌患者衍生的异种移植小鼠模型中进行评估.
主要成果:
- 聚合物自组成纳米粒子,具有强大的体外抗癌活性.
- 通过癌细胞膜溶解对抗耐药和癌症干细胞显著有效.
- 防止癌细胞迁移,并没有诱导多次通过后的抗药性.
- 在异种移植小鼠模型中显示出抗癌效果,与多克索鲁比辛不同.
结论:
- 大分子化疗提供了一种有希望的策略来克服药物耐药性.
- 这种新型的纳米粒子设计有效地向并消除了抗癌细胞.
- 这种方法代表了抗癌疗法发展的新范式.
更多相关视频
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
09:58Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
Published on: December 9, 2016
相关概念视频
Treatment Resistant Cancers
Antidepressant Drugs: MAOIs and Other Agents
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Heart Failure Drugs: Inotropic Agents
Antipsychotic Drugs: Typical and Atypical Agents
Strategies for Assessing and Addressing Confounding
Confounding can be addressed at both the design phase of a study and through analytical methods after data...
